Anti-angiogenic found in tears

Article

Pigment-epithelium-derived factor (PEDF), which is known for its importance in the prevention of neovascularization of the retina, can be found in measurable amounts in the human tear fluid of healthy subjects. It may therefore be important in the regulation of corneal vascularization.

Pigment-epithelium-derived factor (PEDF), which is known for its importance in the prevention of neovascularization of the retina, can be found in measurable amounts in the human tear fluid of healthy subjects. It may therefore be important in the regulation of corneal vascularization, according to a report published online ahead of print by Ophthalmic Research.

Oran Abdiu, MD and co-workers from St Erik's Eye Hospital, Karolinska Institutet, Stockholm, Sweden collected tear fluid samples from 18 healthy individuals and analysed them using a commercial ELISA. Samples were also collected from five patients with pterygium and, as a positive control, two samples were taken from the subretinal fluid of patients following retinal detachment surgery.

The researchers found that PEDF concentrations were below the detection limit (i.e. <0.1 ng/ml) in the majority of samples from healthy subjects. However, PEDF was discovered in three of the samples with significant concentrations of 2, 32 and 53 ng/ml. There were no detectable concentrations among the group with pterygium.

The researchers were therefore able to confirm that PEDF can be found in measurable amounts in human tear fluid of healthy individuals and it may play a role in the effects and regulation of vascularization at the ocular surface.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.